IN VITRO AND IN VIVO EFFICACY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN EPITHELIAL OVARIAN CANCER WITH HER2/NEU OVEREXPRESSION

被引：0
|
作者：
Mutlu, Levent [1 ]
Manavella, Diego [1 ]
Bellone, Stefania [1 ]
Santin, Alessandro [1 ]
机构：
[1] Yale Univ, Obstet Gynecol & Reprod Sci, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷
关键词：
D O I：
10.1136/ijgc-2022-igcs.106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP015/#546
引用
收藏
页码：A54 / A54
页数：1
相关论文
共 50 条
  • [41] Population Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2positive breast cancer subjects: analyses across 12 Phase 1-3 studies
    Li, Claire
    Henning, Stefanie
    Patel, Kashyap
    Hui, Katrina
    van der Vleuten, Gerly
    Abutarif, Malaz
    Garimella, Tushar
    Khatri, Amit
    CANCER RESEARCH, 2024, 84 (09)
  • [42] A PHASE 1/2 STUDY OF SBT6050 COMBINED WITH TRASTUZUMAB DERUXTECAN (T-DXD) OR TRASTUZUMAB AND TUCATINIB WITH OR WITHOUT CAPECITABINE IN PATIENTS WITH HER2-EXPRESSING OR HER2-AMPLIFIED CANCERS
    Klempner, Samuel
    Strickler, John
    Gourley, Lindsey
    Jacquemont, Celine
    Bhatia, Vinona
    Hunder, Naomi
    Odegard, Valerie
    Piha-Paul, Sarina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A426 - A426
  • [43] Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)
    Hingorani, Pooja
    Zhang, Wendong
    Kurmasheva, Raushan
    Zhang, Zhongting
    Wang, Yifei
    Xu, Zhaohui
    Roth, Michael
    Gill, Jonathan
    Harrison, Douglas
    Erickson, Stephen
    Kolb, Edward A.
    Smith, Malcolm
    Houghton, Peter
    Gorlick, Richard
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
    Wolff, Antonio C.
    Mcshane, Lisa M.
    Allison, Kimberly H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (08): : 829 - 831
  • [45] Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Polhamus, Daniel
    Cobbina, Enoch
    Garcia, Ramon
    Yoder, Todd
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma.
    Shitara, Kohei
    Enzinger, Peter C.
    Mohapatra, Avani
    Janjigian, Yelena Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS508 - TPS508
  • [47] Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
    Okamoto, Hiromi
    Oitate, Masataka
    Hagihara, Katsunobu
    Shiozawa, Hideyuki
    Furuta, Yoshitake
    Ogitani, Yusuke
    Kuga, Hiroshi
    XENOBIOTICA, 2020, 50 (10) : 1242 - 1250
  • [48] HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance - Clinical study
    Verri, E
    Guglielmini, P
    Puntoni, M
    Perdelli, L
    Papadia, A
    Lorenzi, P
    Rubagotti, A
    Ragni, N
    Boccardo, F
    ONCOLOGY, 2005, 68 (2-3) : 154 - 161
  • [49] EVALUATION OF HER2/neu EXPRESSION IN OVARIAN EPITHELIAL TUMOURS
    Arya, P. R.
    Varghese, Sheela
    Sankar, S.
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2018, 7 (15): : 1883 - 1887
  • [50] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
    Makker, V.
    Lee, J-Y.
    Oh, D-Y.
    Oaknin, A.
    Puvvada, S. D.
    Cecchi, F.
    Mcewen, R.
    Michelini, F.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240
12345